Abstract 160P
Background
Nano-liposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard treatment for advanced pancreatic cancer after gemcitabine-based chemotherapy. However, there are limited clinical data on its efficacy and safety. We therefore initiated the NAPOLEON-2 study. Imajima et al. have reported the final results of the retrospective portion of the study (ASCO GI, 2023). Here, we report on the pre-planned interim analysis of the prospective portion, focusing on safety.
Methods
This study is an ongoing multicenter observational study that took place in June 2021, with a target number of 150 cases. The primary endpoint was overall survival, with secondary endpoints including response rate, disease control rate, progression-free survival, dose intensity, and adverse events (AEs). According to the protocol regulation, an interim analysis was conducted once reaching half the number of target cases to verify the validity of further enrollment.
Results
The median follow-up period was 5.3 months. The median age was 71 years (range, 45–83), and the study included seven locally advanced cancer cases. Liver (43), peritoneum (28), and lung (21) were the most common metastatic sites. NFF was administered as a 2nd/3rd/4th- or later-line therapy to 44/25/6 cases, respectively. All patients had previously received gemcitabine-based therapy. For the initial dose, nano-liposomal irinotecan (NAL-IRI) or fluorouracil (FU) was reduced in 41 and 26 cases, respectively, mainly because of organ function (17%) and age (15%). Grade 3/4 hematological or non-hematological AEs occurred in 24 and 29 cases, respectively. Frequently observed grade 3/4 AEs were neutropenia (26%) and anorexia (16%). The median relative dose intensity was 71.5% for NAL-IRI and 82.9% for FU. Dose reduction during treatment was observed in 35 cases with NAL-IRI and 34 cases with FU, mainly from neutropenia (19%) and anorexia (13%).
Conclusions
These results reproduced the retrospective portion in the safety of NFF, validating this interim analysis. NFF was safely administered in practical clinical settings, so we determined that enrollment should be continued.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract